The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
Automated parallel capillary electrophoresis system simplifies protein analysis
Collaboration streamlines patient access to oncology clinical trials
Inducts advanced AI-Powered 24x7 remote patient monitoring system
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
Atlas AI combines NVIDIA BioNeMo cloud APIs for intelligent chemical and protein design
Launch innovative vitamin sublingual sprays
Subscribe To Our Newsletter & Stay Updated
